| Similar Articles |
|---|
 |
Chemistry World
September 2007
Derek Lowe |
Column: In the Pipeline Will Phase Zero trials actually help drug development?   |
Bio-IT World
March 8, 2005
John Russell |
Debating Business Models for Bioinformatics Companies Nailing down a single formula for successfully selling bioinformatics products or services has proven elusive. Harvard Business School tackles informatics' basic question: Where's the money? |
The Motley Fool
June 12, 2009
Brian Orelli |
Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side. |
Investment Advisor
December 2005
Greg B. Scott |
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. |
Pharmaceutical Executive
October 1, 2006
Clinton & Koroneos |
Learn & Confirm At Wyeth, a sweeping set of initiatives is transforming the R&D operation - and spotlighting a possible future for drug development. |
Fast Company
December 2009
Erica Westly |
The Price of Winning FDA Approval Approval for a new drug or medical treatment requires extensive -- and expensive -- human trials for safety and effectiveness. |
Bio-IT World
May 7, 2002
Malorye Branca |
In Silico Survivors Facing desperate times, bioinformatics companies revamp, refocus, or perish. |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
Bio-IT World
August 18, 2004
Judy Hanover |
Do ASPs Work for Life Science? Clinical trial data management is a natural fit for the application service providers (ASP) model. But ASPs have not been successful with bioinformatics tools. |
Bio-IT World
September 2006
Mike May |
Working Out the Flow Better management of workflow issues in biotech and pharma could change fundamental aspects of these sciences in the near future. |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
Chemistry World
October 15, 2013
Dinsa Sachan |
Supreme court ruling brings clinical trials to a halt in India The fate of 162 global clinical trials hangs in the balance, as the top Indian court has asked the government to provide more details on their approval process before they can proceed. |
The Motley Fool
December 29, 2006
Brian Lawler |
Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide. |
The Motley Fool
April 26, 2007
Tom Taulli |
Phase Forward's False Funk Ignore its stagnant shares -- new deals should continue this company's growth. |
The Motley Fool
July 27, 2007
Tom Taulli |
A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth. |
Bio-IT World
August 13, 2002
Mark D. Uehling |
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way? |
Bio-IT World
June 12, 2002
Morris R. Levitt |
A New Economic Paradigm for Bio-IT? All who work in the bio-IT industry -- scientists, IT and informatics managers, and executives -- have been aware for some time that we seem to be suspended between an acute sense of crisis and a field of boundless opportunity. |
The Motley Fool
August 2, 2004
Charly Travers |
What's a Drug Worth? The value of small biotech companies is in their investigational drug programs. |
Chemistry World
January 25, 2013
Rajesh Parishwad |
Indian supreme court's anger over unregulated clinical trials The fledgling clinical trials industry in India has been hit by recent revelations of a lack of regulation. Now, the country's supreme court has criticized the body that oversees clinical trials for its inaction in the face of these unethical practices. |
Bio-IT World
June 12, 2002
Beth Schachter |
Informatics Moves to the Head of the Class The race is on to increase the quantity and quality of bio-IT training programs as government and academia bet the need will be great. Will the job market back up that bet? |
Bio-IT World
July 11, 2002
Mike Fitzgerald |
Funding the Future Investor G. Steven Burrill, CEO of Burrill & Company, helps biotech companies fulfill their potential. He talked recently about his view of the bio-IT field. |
Bio-IT World
September 2006
John Otrompke |
Bioinformatics Is Going Back to School A spate of government-funded initiatives are helping to develop innovative bioinformatics curricula, providing more up-to-date and integrated training needed by industry, and preparing incumbent workers to meet the needs of the developing industry. |
Bio-IT World
October 10, 2003
Malorye Branca |
Think Bioinformatics, Think Buffalo The University at Buffalo is getting high-profile help in fulfilling its goal of becoming a bioinformatics heavyweight. |
The Motley Fool
September 28, 2006
Brian Lawler |
Myriad Moves Forward The biotech's new cancer candidate passes phase 1 trials. Investors should take note, and make room for Myriad on their radar screens. |
Bio-IT World
March 10, 2003
Michael Greeley |
Too Much Informatics Did bioinformatics companies forget about the fundamental law of supply and demand? |
Bio-IT World
September 9, 2002
Malorye Branca |
In Like a LION ... The Once and Future King? LION Biosciences CEO Friedrich von Bohlen talks about his undaunted support for his vision for the company. |
Bio-IT World
February 2007 |
Bio*IT World's Coming Attractions 2007 Bio-IT World Conference & Expo preview -- Meet the Keynotes... Oracle Users... Systems are Go... Candid Camera... A Vital IT Alliance... Next Generation Informatics... etc. |
Bio-IT World
September 9, 2002 |
Letters Frustrated in Gene Town... IT for the Biologists, by the Biologists?... |
Bio-IT World
November 19, 2004
Kevin Davies |
The Book on Bioinformatics Research director David Mount talks about his new book "Bioinformatics: Sequence and Genome Analysis," sequence analysis, and teaching bioinformatics |
Inc.
June 1, 2002
Kate O'Sullivan |
High Concept: Fields of Genes As pharmaceutical companies pour hundreds of millions of dollars into the development of new drugs, the newly christened bioinformatics software sector is attracting attention from investors and research labs alike... |
